LP
DNTH icon

LMR Partners’s Dianthus Therapeutics DNTH Stock Holding History

LMR Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.77M Buy
+116,444
New +$6.74M 0.02% 444
2024
Q2 		– Sell
-7,478
Closed -$224K – 1148
2024
Q1 		$224K Buy
+7,478
New +$163K ﹤0.01% 853
2022
Q4 		– Sell
-667
Closed -$15K – 1151
2022
Q3 		$15K Hold
667
– – ﹤0.01% 1176
2022
Q2 		$13K Buy
+667
New +$16.5K ﹤0.01% 1249

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LMR Partners's DNTH Position: Q1 2026 in Review

LMR Partners opened a new position in Dianthus Therapeutics (DNTH) in Q1 2026: 116,444 shares worth $9.77M. The stake represents 0.02% of the portfolio and ranks #444 among its holdings. This is a return to the name: LMR Partners previously reported a position in DNTH as recently as Q1 2024.

LMR Partners first reported a position in DNTH in Q2 2022 and has held it in 4 quarters since. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • LMR Partners held 116,444 shares of Dianthus Therapeutics worth $9.77M as of Q1 2026.
  • Dianthus Therapeutics was a new LMR Partners position in Q1 2026.
  • Dianthus Therapeutics made up 0.02% of LMR Partners's portfolio in Q1 2026, its #444 holding.
  • LMR Partners first reported a position in Dianthus Therapeutics in Q2 2022 and has held it in 4 quarters since.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.